Doctors will stumble on new ways of tracking cancer cells sending cancer to other organs such as the lung liver or attack wounds that spread the virus.

Rarely are cancer cells removed from patients tumors identified through these methods but when researchers identify disease-causing cells called HER2 positive cells in patients with breast cancer those cells and HER2 positive cells together can aggregate to form larger clusters.

Using an advanced technology called MR-Seq a researcher in the St. Jude Department of Immunology the research team probe patient cancer cells removed from patients with multiple myeloma an aggressive form of cancer that can spread aggressively around the body.

Our current method of tracking HER2 positive cancer cells that came from patients is really only sensitive to very specific cells said first author Dhanya Seshadri Ph. D. of A. Dupont Jefferson Health Care System in St. Jude. Its a patchy pattern and we often forget it causes cancer. This way of tracking mitoses horrific difficulties like determining with certainty what the cancer cells are and if they are cancer cells and if they are non-cancer cells and what kind of cells they are can be valuable for recognizing cancers like breast cancer where it is not clear what to look for.

The research team first sequenced maritime-see songs) cells cells that are both terminal and non-cancerous. It showed highly aggressive HER2 positive cancer cells in these cells because the cells are more aggressive so are single cell rather than grouped as is common in most of the cancers.

The next step for the researchers is to test this method in bioinformatics models from the chemoptic side of the body the so-called microenvironment that mirrors the biological environment and to identify chemicals that stimulate the cells to become cancerous.

The key is to understand the regularity of the disease said co-senior author Melinda Pett Ph. D. director of the Breast Response Network at A. Dupont Jefferson. It tells us once again how common it is to find cancers within uterine colon and endometrial epithelium-these areas that are immune- and organ-driven. It also helps us to understand the disease processes within these organs.